Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
July 2, 2008
Pharma may benefit from both new drugs and new uses for old drugs
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: GLG Expert Contributor
The public benefits when new uses are found for old drugs.  The benefit comes more quickly as the pharma company does not need to go through as many early studies to allow the approval for the drug use. However, I believe that pharma realizes that new uses for old drugs is not the way...
June 30, 2008
GSK's Lapatanib: ways from competing with Herceptin
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
In a recent JCO article, Laptanib showed clinical efficacy and acceptable safety in a non-randomized trial involving newly diagnosed patients with advanced oe metastatic breast cancer. Larger trials are needed to confirm efficacy and explore if it is more potent than Genentech's Herceptin. For now,...
June 30, 2008
Avastin for front-line treatment of metastatic breast cancer: Not a big market
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: GLG Expert Contributor
Avastin's recent FDA approval for m-breast cancer ( m-BCA) was lukewarm at best with no overall survival benefit yet and modest PFS data. European regulatory agencies usually require cost efficacy data and more strict data, which are not readily available for Roche/Genetech. The British market is not...
June 30, 2008
The heck with the impact on Roche. How about the patients??
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: GLG Expert Contributor
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
June 30, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: GLG Expert Contributor
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
June 27, 2008
The other shoe falls II: Amgen and J & J will not be happy.
Analysis of: Europe Backs Anemia-Drug Warnings | online.wsj.com
Author: GLG Expert Contributor
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
June 26, 2008
Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
Analysis of: Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty | content.nejm.org
Author: GLG Expert Contributor
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).
June 24, 2008
Molecular Profiling for Epo Stimulating Agents: Trying to 'Stop the Bleeding'
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: GLG Expert Contributor
Use of Epo Stimulating Agents (ESAs) for cancer patients have all but come to a screeching halt when a plattoon of studies came out suggesting that ESAs might actually cause more harm, notably by possibly acting as a growth factor for tumor cells.  Now, reserachers are trying to determine...
June 23, 2008
Amgen as well as J & J: Adding insult to injury......
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: GLG Expert Contributor
Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.
June 20, 2008
Electronic Records?? Great but.......
Analysis of: Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Author: GLG Expert Contributor
Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next91 to 100 of 1053

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637